Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Antiplatelet prasugrel offers coronary stent benefits

Antiplatelet agent prasugrel could offer improved outcomes in patients who have had at least one coronary stent, US researchers report.

A comparison of the combination of thienopyridine, prasugrel and aspirin with clopidogrel plus aspirin in more than 12,800 patients found fewer ischaemic events with the newer combination.

Prasugel reduced definite stent thrombosis by 58% and definite, probable or possible stent thrombosis by 44% compared with the clopidogrel combination.

The Lancet 2008, early online publication

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say